GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » Equity-to-Asset

Annovis Bio (Annovis Bio) Equity-to-Asset : -0.76 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Annovis Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-7.75 Mil. Annovis Bio's Total Assets for the quarter that ended in Dec. 2023 was $10.21 Mil.

The historical rank and industry rank for Annovis Bio's Equity-to-Asset or its related term are showing as below:

ANVS' s Equity-to-Asset Range Over the Past 10 Years
Min: -148.9   Med: -0.76   Max: 0.97
Current: -0.76

During the past 7 years, the highest Equity to Asset Ratio of Annovis Bio was 0.97. The lowest was -148.90. And the median was -0.76.

ANVS's Equity-to-Asset is ranked worse than
91.12% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs ANVS: -0.76

Annovis Bio Equity-to-Asset Historical Data

The historical data trend for Annovis Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio Equity-to-Asset Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial -7.68 0.93 0.97 0.79 -0.76

Annovis Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.79 0.91 0.65 -0.76

Competitive Comparison of Annovis Bio's Equity-to-Asset

For the Biotechnology subindustry, Annovis Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annovis Bio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Annovis Bio's Equity-to-Asset falls into.



Annovis Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Annovis Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-7.751/10.208
=

Annovis Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-7.751/10.208
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Annovis Bio  (NYSE:ANVS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Annovis Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Annovis Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Annovis Bio (Annovis Bio) Business Description

Traded in Other Exchanges
Address
1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
Executives
Henry Iii Hagopian officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White director 227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini director, officer: President and CEO 1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy director 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty officer: Chief Financial Officer 360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M. director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831